Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02293603
Other study ID # CAP-1002 (DYNAMIC)
Secondary ID R44HL095203
Status Active, not recruiting
Phase Phase 1
First received November 5, 2014
Last updated June 17, 2016
Start date November 2014
Est. completion date April 2020

Study information

Verified date June 2016
Source Capricor Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To determine the safety profile of CAP-1002 administered by multi-vessel intracoronary infusion in subjects with DCM. The study will further explore safety and exploratory efficacy endpoints of CAP-1002.


Description:

Eligible subjects will undergo sequential intracoronary infusion of CAP-1002 or placebo in up to three coronary arteries supplying three major cardiac territories to the heart (anterior, lateral, inferior/posterior). After completion of the screening procedures, Phase Ia subjects will receive CAP-1002 administered via intracoronary infusion in a dose escalation, stepwise manner. Phase Ia subjects will be followed at Week 2 and at Months 1, 2, 3, 6 and 12 after CAP-1002 infusion. The first fourteen (14) subjects will receive intracoronary infusion of CAP-1002 in an open-label fashion (Phase Ia). Once all 14 subjects in the Phase Ia have reached the primary safety endpoint (1 month visit), the DSMB will conduct a review of the Phase Ia data and recommend whether to proceed with enrollment of the next 28 subjects in the Phase Ib.


Other known NCT identifiers
  • NCT01815060

Recruitment information / eligibility

Status Active, not recruiting
Enrollment 42
Est. completion date April 2020
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Major Inclusion Criteria:

1. DCM with left ventricular ejection fraction (LVEF) = 35% as determined by a historical TTE within the previous 6 months

2. New York Heart Association (NYHA) Class III or ambulatory Class IV heart failure

3. Use of evidence based medical-therapy (beta-blockers, ACE-inhibitors/angiotensin receptor blockers, aldosterone antagonist) and with or without device-therapy (Implantable cardioverter-defibrillator or cardiac resynchronizing therapy), in accordance with the ACC/AHA guidelines for the management of heart failure, for at least three months prior to enrollment or documented contraindication or intolerance or patient preference

4. Coronary anatomy suitable for Investigational Product (IP) infusion, as determined by the Eligibility Committee (a team of cardiology experts)

5. Ability to provide informed consent and follow-up with protocol procedures

6. Screening cardiac CT left ventriculogram ejection fraction <40% with left ventricular dilatation

7. Age = 18 years

Major Exclusion Criteria:

1. Diagnosis of active myocarditis

2. Immunologic incompatibility with all available Master Cell Banks (MCBs) by single-antigen bead (SAB) serum antibody profiling

3. Left Ventricular Assist Devices (LVAD) or those actively in the process of acquiring one

4. Recent placement of a cardiac pacemaker and/or resynchronization pacing therapy within the past three months or those actively in the process of acquiring one

5. History of sustained ventricular tachycardia (VT) requiring cardiopulmonary resuscitation (with the exception of subjects who subsequently received an ICD)

6. Non-cardiovascular disease with life expectancy of < 3 years

7. Known hypersensitivity to contrast agents

8. Estimated glomerular filtration rate (GFR) < 50 mL/min

9. Active infection not responsive to treatment

10. Active allergic reactions, connective tissue disease or autoimmune disorders

11. History of cardiac tumor, or cardiac tumor demonstrated on screening

12. History of previous stem cell therapy

13. History of treatment with immunosuppressive agents, including chronic systemic corticosteroids, biologic agents targeting the immune system, anti-tumor and anti-neoplastic drugs or anti-vascular endothelial growth factor (VEGF) within 6 months prior to enrollment (not including drug eluting coronary stents)

14. History of receipt of chemotherapeutic agents known to be implicated in cardiac dysfunction [Adriamycin, trastuzumab (Herceptin)]

15. Known moderate-severe aortic stenosis/insufficiency or severe mitral stenosis/regurgitation

16. Participation in an on-going protocol studying an experimental drug or device

17. Current active alcohol or drug abuse or inability to comply with protocol-related procedures

18. Pregnant/nursing women and women of child-bearing potential without use of active and highly reliable contraception

19. Known history of Human Immunodeficiency Virus (HIV) infection

20. Known history of chronic viral hepatitis

21. Abnormal liver function (serum glutamic pyruvic transaminase (SGPT) > 10 times the upper reference range) and/or abnormal hematology (hematocrit < 25%, white blood cells (WBC) < 3000 µl, platelets < 100,000 µl) studies without a reversible, identifiable cause

22. Evidence of tumor on screening of chest/abdominal/pelvic (body) CT scan

23. Any prior organ transplant

24. Being actively listed for, or under active consideration (i.e., work-up) for, a solid organ transplant of any kind

25. Known hypersensitivity to bovine products

26. Known hypersensitivity to dimethyl sulfoxide (DMSO)

27. Any malignancy within past 2 years (except for in-situ non-melanoma skin cancer and in-situ cervical cancer)

28. Any prior radiation therapy/treatment to the chest

29. Uncontrolled diabetes (HbA1 >9.0)

30. Any condition or other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Biological:
Allogeneic Cardiosphere-Derived Cells (CDCs)
Intracoronary delivery of CAP-1002 or placebo

Locations

Country Name City State
United States Cedars-Sinai Medical Center Los Angeles California

Sponsors (4)

Lead Sponsor Collaborator
Capricor Inc. Cedars-Sinai Medical Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects that experience new TIMI flow 0-2 or TIMI myocardial perfusion grade (TMPG) 0-2. Intraprocedural Yes
Primary Proportion of subjects that experience acute myocarditis, possibly attributable to CAP-1002. In order to be considered related to CAP-1002, humoral or cellular or immune reaction specific to CAP-1002 must also be documented. Within one month of intracoronary infusion Yes
Primary Proportion of subjects that experience ventricular tachycardia or ventricular fibrillation resulting in death, appropriate discharge of an ICD or requiring medical intervention. During or within 72 hours of intracoronary infusion Yes
Primary Proportion of subjects that experience sudden unexpected death occurring within one hour of symptom onset, or un-witnessed death in a person previously observed to be well within the preceding 24 hours without an identified cause. During or within 72 hours of intracoronary infusion Yes
Primary Proportion of subjects that experience major adverse cardiac events (MACE), including death, non-fatal myocardial infarction and re-hospitalization for cardiovascular event (including heart failure hospitalizations). During or within 72 hours of intracoronary infusion Yes
Secondary Acute myocarditis possibly attributable to CAP-1002. In order to be considered related to CAP-1002, humoral or cellular immune reaction specific to CAP-1002 must also be documented. During the six & twelve month follow-up period Yes
Secondary Ventricular tachycardia or ventricular fibrillation resulting in death or requiring medical intervention or appropriate discharge of an ICD. During the six & twelve month follow-up period Yes
Secondary Sudden unexpected death defined as occurring within one hour of symptom onset, or unwitnessed death in a person previously observed to be well within the preceding 24 hours without an identified cause. During the six & twelve month follow-up period Yes
Secondary Major adverse cardiac events (MACE), including death, non-fatal myocardial infarction, hospitalization for cardiovascular event, emergency room treatment for heart failure, left ventricular assist device or heart transplant. During the six & twelve month follow-up period Yes
Secondary Any hospitalization due to a cardiovascular cause or related to CAP-1002 (or placebo in Phase Ib). During the six & twelve month follow-up period Yes
Secondary Any inter-current cardiovascular illness or one related to CAP-1002 (or placebo in Phase Ib) which prolongs hospitalization. During the six & twelve month follow-up period Yes
Secondary Development of, or an increase in the frequency of, VT with a duration of 30 seconds or longer ascertained by protocol-mandated ECG ambulatory monitoring. During the six & twelve month follow-up period Yes
Secondary Development of increased anti-Human Leukocyte Antigen (HLA) antibody levels with development of sensitization to HLA antigens specific to the CAP-1002 CDC donor at immunologically significant titers. During the six & twelve month follow-up period Yes
Secondary Total number of appropriate ICD firings. During the six & twelve month follow-up period Yes
Secondary Peak elevation in troponin and CKMB levels following CAP-1002 or placebo infusion. Through Month 1 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy

External Links